Published in Cancer Weekly, June 8th, 2004
"We are pleased to have Eligard competing in Germany, the third largest market in the world for this type of treatment," said David R. Bethune, chairman and chief executive officer at Atrix. "We look forward to other European approvals and launches over the next several years."
In early December 2003 and early January 2004, MediGene received marketing authorization...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.